We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Laboratory Features of Trichinellosis and Eosinophilia Threshold Determined

By LabMedica International staff writers
Posted on 01 Dec 2022

Trichinella nativa is a nematode worm, one of the species of the genus Trichinella, found in arctic and subarctic regions. More...

It is highly pathogenic and has a high resistance to freezing. It is encapsulated, and infects a wide variety of mammals and birds.

T. nativa is a species commonly found in omnivores and carnivores such as wild boars, foxes, raccoon dogs and bears. In the Arctic, the corpses of animals that die may get frozen and later be consumed by scavengers. This worm remains viable even after being frozen at −18 °C for four years. Eosinophilia is a well-characterized feature of infection that is readily available for most cases.

Infectious Disease Scientists at the McGill University Health Centre (Montreal, QC, Canada) and their colleagues reviewed all requests for Trichinella serologic testing sent from Quebec to the National Reference Centre for Parasitology (Toronto, ON, Canada). They identified 43 cases of trichinellosis and a set of 31 region-matched controls. Information on signs and symptoms was available for only 19/43 case-patients, but demographic, laboratory, and clinical outcomes were well documented. Case-patients had a median age of 40 years and were mostly female (30/43, 69.8%).

Laboratory information was available for 41/43 case-patients. Features of Trichinella infection presumptively caused by T. nativa, are similar to those reported for T. spiralis infection, including elevated creatinine kinase and eosinophilia. The variable that differed most between cases and controls was peak absolute eosinophilia (5.35 versus 0.80 × 109 cells/L). Using ROC analysis, they identified an absolute eosinophilia threshold of >0.8 × 109 cells/L, which identified all cases in this series with a specificity of 71%.

The authors noted that automated flags and reflex testing in the local laboratory has now incorporated the threshold identified in their analysis. In the absence of a defined alternative diagnosis, eosinophil counts of >0.80 ×109 cells/L should prompt clinical consideration of trichinellosis and further investigation. The study was published in the November 2022 edition of the journal Emerging Infectious Diseases.

Related Links:
McGill University Health Centre
National Reference Centre for Parasitology 


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.